37
Trails Edge Biotechnology USA Fund, LP updates its Form D — $206M sold
Fund raise update · Hedge fund · Open-ended · Offering Indefinite · Sold $206M · ATLANTA, GA · filed 2026-06-25
3(c)(7) — qualified purchasers
97
Trails Edge Biotechnology USA Fund, LP files an open-ended hedge fund fund
New fund · Hedge fund · Pre-first close · ATLANTA, GA · Form D filed 2025-06-25 · all Trails Edge Biotechnology vehicles
3(c)(7) — qualified purchasersPre-first closeFirst filing by this entityFirst-time managerNeeds prime broker / custody
Why now — by persona
Relevant to: Fund administrator, Fund audit & tax, Fund-formation counsel, Custodian / prime broker, Compliance consultant / RIA registration. Lead card pending.
People on the filing
| Ortav Yehudai | Executive Officer |
| - Trails Edge Biotechnology Fund GP, LP | General Partner |
| - Trails Edge Capital Partners, LP | Investment Manager |
| Matthew Diaz | Executive Officer |
Signed by Ortav Yehudai, Chief Investment Officer.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.